Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethanolic extract of Paris polyphylla (EEPP) is a natural product extract derived from the rhizome of the traditional Chinese medicinal herb *Paris polyphylla*. It is characterized by a high content of steroidal saponins, specifically polyphyllins and pennogenin 3-O-beta-chacotrioside, which typically comprise over 80% of the extract. EEPP has been investigated in preclinical studies for its potent anticancer activities across various malignancies, including colorectal, prostate, liver, and breast cancers. Its mechanism of action involves the induction of autophagy, apoptosis, and cell cycle arrest. Research indicates that EEPP can act synergistically with standard chemotherapeutic agents like doxorubicin and 5-fluorouracil. Currently, it is primarily studied by academic institutions in Asia as an experimental therapeutic agent rather than a commercial drug product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethanolic extract of Paris polyphylla.